Daré Bioscience (NasdaqCM:DARE) Q3 2025 Earnings Call November 13, 2025 04:30 PM ET Speaker1Welcome to the conference call hosted by Daré Bioscience to review the company's third quarter 2025 financial results and to provide a business update. This call is being recorded. My name is Jericho, and I will be your operator today. With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer, and MarDee Haring-Layton, Chief Accounting Officer. Ms. Haring-Layton, please proceed.Speak ...

Event to Explore What Makes DARE to PLAY™ a First-of-Its-Kind Topical Sildenafil Cream for Women, Review Supporting Clinical Data, and Discuss 503B Pathway to Commercial Availability, Expected Before Year-EndSAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced it will host a live webinar on Monday, November 17, 2025, on ...

[Music] Vagina. Vagina. Yes, I said it in front of you all on a stage into a microphone. And guess what? The world didn't end. But let's be honest, some of you flinched. Some of you looked down. And some of you might be still wanting this to turn into a joke. >> It won't. I say it every day. I'm a doctor. I'm an aesthetic gynecologist. And I talk about vaginas all day. Not in secrecy, not in shame, not in whisper, not as something dirty, embarrassing or as a taboo. I am an aesthetic gynecologist. I talk abo ...

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2025, to review its financial results for the quarter ended September 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (t ...

[Music] Growing up in Ethiopia, I had a relatively comfortable life. I did not fetch water. I did not walk miles to school.I had a toilet at home. It wasn't luxurious, but it was comfortable. It was private.I never thought about it until I moved back to Ethiopia in my early 20s after studying in the US. That's when everything changed. As I traveled throughout the country, I realized there were no toilets, not just in rural villages.But alongside highways, schools, markets, I started planning my entire day a ...

This is a big issue. We've been talking about it for years, about the amount of money that's either shifting into the hands of women. What it means, what the differences are.I am curious, and maybe not everybody's aware of all the work that you guys are doing. You have this very specific mission at Pivotal. Remind everybody what you're up to, and I am curious about what it means on a day to day basis, what you're looking forward to invest in relationships and so on.Yes. Again, well, thank you for having me. ...

Core Insights - LifeMD, Inc. has appointed Dr. Tara Scott as ambassador and clinical advisor for its women's health program, focusing on areas such as perimenopause, menopause, hormonal balance, and long-term wellness [1][3][6] Company Commitment - The appointment of Dr. Scott reflects LifeMD's dedication to creating a comprehensive women's health offering, addressing underdiagnosed and underserved medical aspects [3][4] Program Features - LifeMD's virtual women's health program includes: - Virtual consultations combining clinical expertise, personalized therapies, and lifestyle strategies for long-term health [5] - A holistic approach with tiered subscriptions, including lab access, mail-order prescriptions, and dietitian support [5] - LifeMD+ membership providing 24/7 urgent and primary care access, prescription renewals, and a marketplace of wellness products [5] Dr. Scott's Expertise - Dr. Scott is a board-certified obstetrician/gynecologist and menopause specialist with over 25 years of experience, recognized for her research-backed hormonal balancing strategies [6][7] Market Opportunity - Women's health, particularly menopause and osteoporosis, remains underserved, with only 25% of women seeking treatment for menopause-related symptoms and over two-thirds of osteoporosis cases undiagnosed [7] - The projected market opportunity for menopause and osteoporosis is estimated to be $60-70 billion by 2030, significantly larger than current market size [7]

Women's Health & Funding - Less than 1% of funding is spent on women over 40 [3] - Women live 20% more of their lives with chronic disease or mental health disorders [3] - 50% of patients with unexplained infertility have endometriosis [3] - It takes women 7 to 10 years to get an endometriosis diagnosis after symptoms start [3] Menstrual Cycle & Health - Irregular menstrual cycles should be a cause for concern [1] - Lack of a period is harmful to long-term health, brain health, mental health, low energy, mood, and libido [1] Women's Health Discussions & Education - There is a lack of public discussion and education regarding women's health issues [2][3][4] - Patients often normalize pain, delaying diagnosis and treatment [4]

Core Insights - Knight Therapeutics Inc. has relaunched MYFEMBREE, a treatment for uterine fibroids and endometriosis, in Canada, enhancing its women's health portfolio [1][4]. Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [7]. Product Details - MYFEMBREE is a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, approved by Health Canada in September 2023, and is the first oral prescription treatment for managing heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis in pre-menopausal women [3][4]. - The total sales for gonadotropin-releasing hormone receptor (GnRH) agonist and antagonist products for endometriosis and uterine fibroids in Canada are estimated at $45 million, with a five-year CAGR of 8% [3]. Market Context - Uterine fibroids affect 20-30% of women of reproductive age, with 70-80% detected by age 50, often leading to symptoms like heavy menstrual bleeding and pelvic pain [5]. - Endometriosis affects approximately 10% of reproductive-aged women globally, with significant diagnostic delays and limited treatment options available [6].

Health & Wellness Industry Focus - The industry emphasizes the importance of listening to the body's subtle signals before they escalate into more serious issues [2][4] - The industry highlights the significance of addressing the underlying causes of health issues, rather than solely focusing on medical diagnoses and treatments [2][3] - The industry promotes a holistic approach to health, integrating medical advice with self-awareness and personal understanding [3] Personal Health Management - The individual experienced an eight-year period of hormonal imbalance and amenorrhea, leading to emotional distress and disconnection from the body [1] - The individual initially ignored the body's early warning signs (irregular periods) and instead intensified efforts in academic and physical pursuits [2] - The individual's turning point involved a conscious decision to prioritize personal health and listen to the body's needs, leading to the restoration of her menstrual cycle and overall well-being [2] Recommendations - The industry advises individuals to seek medical advice while also exploring the deeper questions their bodies might be asking [3] - The industry encourages individuals to view their bodies as allies rather than adversaries, recognizing that physical symptoms often carry important messages [4]